Eli Lilly Joins Tech Players In The $1T Market Capitalization Club

The company’s GLP-1 drugs, Zepbound and Mounjaro, have driven investor appetite and pushed its share price by about 40% this year.
A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)
A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)
Profile Image
Anan Ashraf·Stocktwits
Published Nov 21, 2025   |   10:23 AM EST
Share
·
Add us onAdd us on Google

Eli Lilly & Co. (LLY) hit a market capitalization of $1 trillion on Friday after its shares rose as much as 1.7% on optimism surrounding the company’s GLP-1 category of drugs.

With the rise, Lilly is now the first healthcare company to cross the $1 trillion valuation benchmark, joining technology companies including Tesla.

The company’s GLP-1 drugs, Zepbound and Mounjaro, have driven investor appetite and pushed its share price by about 40% this year. In the three months through the end of September, the company reported combined Zepbound, Mounjaro revenue of about $10 billion. 

Get updates to this developing story directly on Stocktwits.

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy